| Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts E Walsby, V Walsh, C Pepper, A Burnett, K Mills haematologica 93 (5), 662-669, 2008 | 109 | 2008 |
| A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine E Walsby, G Pratt, H Shao, AY Abbas, PM Fischer, TD Bradshaw, ... Oncotarget 5 (2), 375, 2014 | 94 | 2014 |
| Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling L Al Shaer, E Walsby, A Gilkes, A Tonks, V Walsh, K Mills, A Burnett, ... British journal of haematology 141 (4), 483-493, 2008 | 67 | 2008 |
| The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine E Walsby, M Lazenby, C Pepper, AK Burnett Leukemia 25 (3), 411-419, 2011 | 65 | 2011 |
| The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine EJ Walsby, SJ Coles, S Knapper, AK Burnett Haematologica 96 (3), 393, 2011 | 65 | 2011 |
| Phosphoramidates of 2′-β-d-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism Y Mehellou, R Valente, H Mottram, E Walsby, KI Mills, J Balzarini, ... Bioorganic & Medicinal Chemistry 18 (7), 2439-2446, 2010 | 58 | 2010 |
| Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73 F Lam, AY Abbas, H Shao, T Teo, J Adams, P Li, TD Bradshaw, ... Oncotarget 5 (17), 7691, 2014 | 57 | 2014 |
| Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration M Pasikowska, E Walsby, B Apollonio, K Cuthill, E Phillips, E Coulter, ... Blood, The Journal of the American Society of Hematology 128 (4), 563-573, 2016 | 50 | 2016 |
| The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells E Walsby, L Pearce, AK Burnett, C Fegan, C Pepper Oncotarget 3 (5), 525, 2012 | 49 | 2012 |
| Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia E Walsby, A Buggins, S Devereux, C Jones, G Pratt, P Brennan, C Fegan, ... Blood, The Journal of the American Society of Hematology 123 (23), 3607-3617, 2014 | 47 | 2014 |
| Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX‐2 C Pepper, JG Mahdi, AGS Buggins, S Hewamana, E Walsby, E Mahdi, ... Cell proliferation 44 (4), 380-390, 2011 | 35 | 2011 |
| The HSP 90 inhibitor NVP‐AUY 922‐AG inhibits the PI 3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells EJ Walsby, M Lazenby, CJ Pepper, S Knapper, AK Burnett British journal of haematology 161 (1), 57-67, 2013 | 32 | 2013 |
| Increased frequency of CD4+PD‐1+HLA‐DR+ T cells is associated with disease progression in CLL L Elston, C Fegan, R Hills, SS Hashimdeen, E Walsby, P Henley, ... British Journal of Haematology 188 (6), 872-880, 2020 | 30 | 2020 |
| Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition C Pepper, AGS Buggins, CH Jones, EJ Walsby, F Forconi, G Pratt, ... Leukemia 29 (3), 744-747, 2015 | 28 | 2015 |
| TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target E Kennedy, E Coulter, E Halliwell, N Profitos-Peleja, E Walsby, B Clark, ... Blood, The Journal of the American Society of Hematology 137 (22), 3064-3078, 2021 | 26 | 2021 |
| Nucleoside Analogues of Cladribine Produce Enhanced Responses in Cell Lines. E Walsby, C Congiatu, A Schwappach, V Walsh, AK Burnett, C McGuigan, ... Blood 106 (11), 3369, 2005 | 15 | 2005 |
| Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit nuclear factor-κB activity and synergize with bortezomib and ibrutinib in hematologic cancers T Lewis, DB Corcoran, DE Thurston, PJ Giles, K Ashelford, EJ Walsby, ... haematologica 106 (4), 958, 2021 | 7 | 2021 |
| FUS expression alters the differentiation response to all‐trans retinoic acid in NB4 and NB4R2 cells EJ Walsby, AF Gilkes, A Tonks, RL Darley, KI Mills British journal of haematology 139 (1), 94-97, 2007 | 7 | 2007 |
| The NF-κB Inhibitor LC-1 Has Single Agent Activity in Multiple Myeloma Cells and Synergizes with Bortezomib EJ Walsby, G Pratt, S Hewamana, PA Crooks, AK Burnett, C Fegan, ... Molecular cancer therapeutics 9 (6), 1574-1582, 2010 | 5 | 2010 |
| The Aurora Kinase Inhibitor AZD1152 Causes Perturbation of Cell Cycle Distribution in Cell Lines and Primary AML Samples. E Walsby, V Walsh, C Pepper, K Mills, AK Burnett Blood, The Journal of the American Society of Hematology 106 (11), 2759-2759, 2005 | 4 | 2005 |
